Jun 27 2025 This Week in Cardiology

FDA approves triple-drug polypill, a change of opinion, a deep dive into invasive pulmonary embolism therapies, heart disease trends, and diabetes care is on fire are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I FDA News in HTN

• FDA announcement https://george-medicines.com/george-medicines-announces-fda-approval-of-widaplik-telmisartan-amlodipine-and-indapamide-a-new-single-pill-combination-treatment-for-hypertension-in-adults-including-initial-treatment/
• Lancet Study https://doi.org/10.1016/S0140-6736(24)01744-6
• JACC study vs placebo https://www.jacc.org/doi/abs/10.1016/j.jacc.2024.08.025
• JAMA Cardiology Meta-analysis https://jamanetwork.com/journals/jamacardiology/fullarticle/2804313

II Invasive PE Therapy

• EHJ-Open review: https://academic.oup.com/ehjopen/article/5/3/oeaf071/8156689

• PEITHO Trial https://www.nejm.org/doi/10.1056/NEJMoa1302097
• REAL PE Observational Study https://pmc.ncbi.nlm.nih.gov/articles/PMC11308131/

III Heart Disease Trends

• King et al https://www.ahajournals.org/doi/10.1161/JAHA.124.038644

IV Diabetes Coverage

• Medscape Link https://www.medscape.com/viewcollection/37830

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [e-mail]